Logo SUPERTROUT
 

Recombinant vaccines are based on the expression of immunogenic target regions of a pathogen expressed in a heterologous host from which the protective antigen is purified and used in vaccine formulation. For developing a protein antigen-based vaccine, the starting point is the characterization of multiplex protein compounds from bacterial pathogens by two dimensional denaturing polyacrylamide gel electrophoresis (2D-SDS-PAGE). Western blot analysis of sera collected from infected/survivor fish led to reveal the most immunogenic antigen which are easily recognized by host immune system, inducing a response. Once immunogenic proteins have been identified, it is possible to produce them in large quantities with recombinant DNA technology, purify them and use it to vaccinate fish. The production of recombinant proteins has several advantages: it is economical to cultivate the bacteria, producing vaccines on a large scale, and furthermore these vaccines are safe and economical in comparison to live attenuated bacteria-based vaccines, which may revert to pathogenic agents. Several recombinant protein-based vaccines are commercially available and important fish diseases were successfully countered using recombinant vaccines, as reported in chapter 17 of Biotechnological approaches to fish vaccine of Genomics and Biotechnological Advances in Veterinary, Poultry, and Fisheries, (2019).

Actually, autologous and commercial adjuvated vaccines are available for lactococcosis. All these  vaccines have to be administered by injection with procedures that sometimes are too complex and expensive for small-scale farming systems. Their efficacy is limited in space (autologous) and time. This issue will be addressed, in SUPERTROUT Project, by changing the production and administration methods, trying to develop a recombinant-protein vaccine to be administered by immersion. This is the key objective of Work Package 3 of the SUPERTROUT Project, in which the skills and knowledge of the different Partners will be combined to develop an effective vaccine to combat lactococcosis in rainbow trout.

Contatti

Istituto Zooprofilattico Sperimentale del Piemonte, Liguria e Valle d'Aosta, Via Bologna 148, 10154 Torino 

C.F. / P.IVA:05160100011

Codice univoco IPA UF6CXU

PEC: izsto@legalmail.it

Amministrazione trasparente

I dati personali pubblicati sono riutilizzabili solo alle condizioni previste dalla direttiva comunitaria 2003/98/CE e dal d.lgs. 36/2006

Amministrazione trasparente (fino al 15.12.2022)

Piano Transizione Digitale 22-24

Il Piano di Transizione Digitale 2022-2024 deliberato con Delibera del D.G. n. 0000116/B204/2023 del 28/08/2023

Seguici su

facebook